NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections ...

Indaptus Therapeutics (INDP) provided an update on key pharmacodynamic findings from the weekly dosing cohort of its ongoing Phase 1 trial of ...

Indaptus Therapeutics, Inc. (NASDAQ:INDP) announced it advanced to a new expansion arm of its Phase 1b/2 clinical trial of ...

Indaptus Therapeutics, Inc. has announced the approval of new patents in China, Japan, and Israel for its Decoy platform, which involves the use of Decoy bacteria compositions aimed at treating ...

Indaptus Therapeutics announced significant progress in its Phase 1 trial of Decoy20, with over 20 patients enrolled in the weekly dosing cohort. Initial clinical data shows promising ...

Indaptus Therapeutics has a 1 year low of $0.70 and a 1 year high of $3.10. The firm has a market cap of $11.65 million, a price-to-earnings ratio of -0.48 and a beta of 1.60.

NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral ...

Indaptus Therapeutics, Inc. (NASDAQ:INDP – Get Free Report) was the target of a large decrease in short interest in the month of February.As of February 28th, there was short interest totalling ...

NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral ...

NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral ...

Indaptus began a new expansion phase of its Decoy20 trial, combining it with BeiGene’s tislelizumab to assess safety and anti-tumor activity The company expects its cash reserves to fund ...